Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1921 plus adebrelimab in advanced NSCLC
NCT06480136Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jul 2024
- Primary completion
- Jun 2027
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
01
Overview
A Phase 2 trial of tizetatug rezetecan in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
tizetatug rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06480136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06480136.